Amgen : Update Regarding COVID-19

Amgen Update Regarding COVID-19

March 6, 2020

As the COVID-19 situation evolves globally, Amgen continues to provide an uninterrupted supply of medicines for patients around the world. We have taken action to support the health and well-being of our staff members and to activate our business continuity plans.

Staff and Community

• The health and safety of our staff members remains a top priority.
• Globally, Amgen has suspended international business travel through April 17.
• We have suspended attendance at medical congresses, conferences and other large events through April 17.
• We are supporting our staff, including those who are working from home, and are leveraging virtual meeting technology.
• We have activated our business continuity plans to avoid or minimize business disruption and ensure the well-being of our staff.
• Enhanced cleaning procedures and visitor screening are being implemented at all Amgen locations.

Supply of Our Medicines

• Amgen continues to provide an uninterrupted supply of medicines for patients around the world. Based on inventory levels, we do not anticipate a shortage of our medicines due to COVID-19 at this time.
• We are monitoring our raw material inventory levels and taking additional measures to mitigate against interruption.

Clinical Trials

• We have a vast amount of clinical work going on at investigational sites across the globe. We are monitoring this dynamic situation closely.

Impact to Our Business

• Amgen continues to provide an uninterrupted supply of medicines for patients around the world.
• We don't know the extent to which COVID-19 (coronavirus) will continue to spread and impact society.
• At this stage, we cannot rule out future impact on our business including sales, manufacturing and clinical trials.